AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q1 2023 Earnings Call Transcript
Operator: Hello, welcome to the AcelRx First Quarter 2023 Financial Results Conference Call.
Acelrx Pharmaceuticals Inc (ACRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 316,460 | $208,231 | 0% | |
| 2. | Tang Capital Management Kevin C. Tang | 195,000 | $128,310 | 0.01% | |
| 3. | Millennium Management Israel Englander | 93,390 | $61 | 0% | |
| 4. | Renaissance Technologies Jim Simons | 40,482 | $27 | 0% | |
| 5. | Armistice Capital Steven Boyd | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.22 | 46,400 | Officer, Director | 1,016,919 | 2022-06-07 | Filing | |
| $1.29 | 100,000 | Director | 178,750 | 2020-06-15 | Filing | |
| $1.29 | 100,000 | Director | 178,750 | 2020-06-15 | Filing | |
| $1.33 | 7,547 | Officer, Director | 468,757 | 2020-06-15 | Filing | |
| $1.78 | 25,000 | Director | 243,750 | 2019-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 5,216 | Officer | 29,795 | 2018-10-15 | Filing | |
| $5.00 | 28,351 | Officer | 54,061 | 2018-10-15 | Filing | |
| $4.50 | 6,953 | Officer | 35,011 | 2018-09-24 | Filing | |
| $5.29 | 10,161 | Officer | 41,964 | 2017-10-02 | Filing | |
| $0.00 | 13,827 | Officer | 68,504 | 2017-09-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 157,772 | $103,814 | 0% | |
| 2. | 92,088 | $60,594 | 0% | |
| 3. | 60,022 | $39,494 | 0% | |
| 4. | 40,587 | $26,706 | 0.01% | |
| 5. | 28,400 | $18,744 | 0% |
News See All
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript
Operator: Welcome to the AcelRx 2022 Full Year and Fourth Quarter Financial Results Conference Call.
5 Cheap Healthcare Stocks to Buy in 2023
Three of the 943 hedge funds part of Insider Monkey's database had bought Molecular Partners AG (NASDAQ:MOLN)'s shares during Q4 2022.
5 Stocks with the Lowest PE Ratio
Catalyst Biosciences, Inc. (NASDAQ:CBIO) is a clinical-stage biotech company. In December, Catalyst Biosciences, Inc.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript
Operator: Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx's website at www.acelrx.com.
10 Cheapest Stocks With Biggest Upside
In this article, we discuss the 10 cheapest stocks with the biggest upside.
Is AcelRx Pharmaceuticals (ACRX) A Good Stock To Buy Now?
In this article we are going to use hedge fund sentiment as a tool and determine whether AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is a good investment right now.
Hedge Funds Have Never Been Less Bullish On AcelRx Pharmaceuticals Inc (ACRX)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Is AcelRx Pharmaceuticals Inc (ACRX) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second ...
Hedge Funds Have Never Been More Bullish On AcelRx Pharmaceuticals Inc (ACRX)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because...
Billionaire Hedge Funds
